SE462140B - Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdel - Google Patents
Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdelInfo
- Publication number
- SE462140B SE462140B SE8305665A SE8305665A SE462140B SE 462140 B SE462140 B SE 462140B SE 8305665 A SE8305665 A SE 8305665A SE 8305665 A SE8305665 A SE 8305665A SE 462140 B SE462140 B SE 462140B
- Authority
- SE
- Sweden
- Prior art keywords
- iron
- solution
- iii
- preparation
- acetate
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title claims description 9
- 230000001225 therapeutic effect Effects 0.000 title 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 53
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 229910052742 iron Inorganic materials 0.000 claims description 24
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical compound [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims description 12
- PVFSDGKDKFSOTB-UHFFFAOYSA-K iron(3+);triacetate Chemical compound [Fe+3].CC([O-])=O.CC([O-])=O.CC([O-])=O PVFSDGKDKFSOTB-UHFFFAOYSA-K 0.000 claims description 10
- 238000001256 steam distillation Methods 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 7
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 claims description 5
- 239000004480 active ingredient Substances 0.000 claims description 5
- 229940099563 lactobionic acid Drugs 0.000 claims description 5
- 238000005292 vacuum distillation Methods 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000007911 parenteral administration Methods 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 43
- 238000002347 injection Methods 0.000 description 14
- 239000007924 injection Substances 0.000 description 14
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 9
- 238000001669 Mossbauer spectrum Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- MSNWSDPPULHLDL-UHFFFAOYSA-K ferric hydroxide Chemical compound [OH-].[OH-].[OH-].[Fe+3] MSNWSDPPULHLDL-UHFFFAOYSA-K 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 3
- 239000013110 organic ligand Substances 0.000 description 3
- 230000003204 osmotic effect Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- MCDLETWIOVSGJT-UHFFFAOYSA-N acetic acid;iron Chemical compound [Fe].CC(O)=O.CC(O)=O MCDLETWIOVSGJT-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 150000002505 iron Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010024769 Local reaction Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 230000000240 adjuvant effect Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 238000003926 complexometric titration Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000005595 deprotonation Effects 0.000 description 1
- 238000010537 deprotonation reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229960004887 ferric hydroxide Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 150000004698 iron complex Chemical group 0.000 description 1
- 150000002506 iron compounds Chemical class 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000003918 potentiometric titration Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H23/00—Compounds containing boron, silicon, or a metal, e.g. chelates, vitamin B12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
- C07F15/02—Iron compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU328182A HU187167B (en) | 1982-10-15 | 1982-10-15 | Process for producing pharmaceutical solution of new type polynuclear iron/iii/ mixed complex activity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8305665D0 SE8305665D0 (sv) | 1983-10-14 |
| SE8305665L SE8305665L (sv) | 1984-04-16 |
| SE462140B true SE462140B (sv) | 1990-05-14 |
Family
ID=10963435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8305665A SE462140B (sv) | 1982-10-15 | 1983-10-14 | Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdel |
Country Status (11)
| Country | Link |
|---|---|
| AT (1) | AT385655B (de) |
| BE (1) | BE897980A (de) |
| BG (1) | BG49708A3 (de) |
| DE (1) | DE3337506A1 (de) |
| DK (1) | DK476583A (de) |
| ES (1) | ES8406196A1 (de) |
| FI (1) | FI80830C (de) |
| FR (1) | FR2534589B1 (de) |
| GB (1) | GB2129821B (de) |
| HU (1) | HU187167B (de) |
| SE (1) | SE462140B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3728814A1 (de) * | 1987-08-28 | 1989-03-30 | Lentia Gmbh | Loesung zur anwendung als spuelfluessigkeit in der zerstoerung von koerperfremden ablagerungen in menschlichen und tierischen geweben oder koerperhohlraeumen |
| DE4445772A1 (de) * | 1993-12-27 | 1995-06-29 | Loeser Thomas Dr Ing | Verfahren zur Ermittlung der Arzneimittelzusammensetzung |
| DE19712493A1 (de) * | 1997-03-25 | 1998-10-01 | Univ Karlsruhe | Pharmazeutische Zubereitung, enthaltend eine Eisen-Calcium-Polyolato-Verbindung und deren Verwendung |
| DE10249552A1 (de) | 2002-10-23 | 2004-05-13 | Vifor (International) Ag | Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel |
| US20040170724A1 (en) | 2003-02-28 | 2004-09-02 | Kraft Foods Holdings, Inc. | Mineral complexes of lactobionic acid and method of using for mineral fortification of food products |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE862482C (de) * | 1950-05-14 | 1953-01-12 | Merck Chem Fab E | Verfahren zur Darstellung haltbarer, injizierbarer Loesungen von Salzen des dreiwertigen Eisens |
| DE938502C (de) * | 1953-02-27 | 1956-02-02 | Benger S Ltd | Verfahren zur Herstellung einer kolloidalen Eisenzubereitung |
| GB978485A (en) * | 1960-10-26 | 1964-12-23 | Astra Apotekarnes Kem Fab | Iron preparations for intramuscular injection |
| DE1293144B (de) * | 1964-11-04 | 1969-04-24 | Hausmann Ag Labor | Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid |
| DK122890B (da) * | 1964-12-29 | 1972-04-24 | J Reumert | Fremgangsmåde til fremstilling af ferrihydroxiddextrankomplekser. |
| DE1617463A1 (de) * | 1965-11-20 | 1971-04-08 | Bayer Ag | Verfahren zur Herstellung von injizierbaren kolloidalen Eisenzubereitungen |
| GB1149137A (en) * | 1966-10-28 | 1969-04-16 | H C F Porsche K G Ing | Screw outboard drive for boats |
| AT279048B (de) * | 1967-07-04 | 1970-02-25 | Pharmazeutische Fabrik Montavit Gmbh | Verfahren zur Herstellung neuer, löslicher und stabiler organischer Eisen(III)-Komplexverbindungen und Injektionslösungen davon |
| DE2527158A1 (de) * | 1975-06-18 | 1976-12-23 | Herz Eberhard | Arzneimittel zur behandlung von infektionskrankheiten und von nicht nachweisbar durch mikroorganismen ausgeloeste entzuendungen in der human- und veterinaermedizin |
| JPS6039681B2 (ja) * | 1976-01-01 | 1985-09-07 | 日本臓器製薬株式会社 | デキストリン・クエン酸・第二鉄多核複合体及び該複合体を含有する非経口用鉄剤 |
| GB2006243B (en) * | 1977-09-29 | 1982-07-14 | Atomic Energy Authority Uk | Compounds |
| DE3026868C2 (de) * | 1980-07-16 | 1986-03-13 | Laboratorien Hausmann AG, St. Gallen | Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung |
-
1982
- 1982-10-15 HU HU328182A patent/HU187167B/hu not_active IP Right Cessation
-
1983
- 1983-10-12 FI FI833707A patent/FI80830C/fi not_active IP Right Cessation
- 1983-10-12 AT AT363983A patent/AT385655B/de not_active IP Right Cessation
- 1983-10-13 BE BE0/211691A patent/BE897980A/fr not_active IP Right Cessation
- 1983-10-14 GB GB08327633A patent/GB2129821B/en not_active Expired
- 1983-10-14 SE SE8305665A patent/SE462140B/sv not_active IP Right Cessation
- 1983-10-14 FR FR8316377A patent/FR2534589B1/fr not_active Expired
- 1983-10-14 DE DE19833337506 patent/DE3337506A1/de active Granted
- 1983-10-14 ES ES526481A patent/ES8406196A1/es not_active Expired
- 1983-10-14 DK DK476583A patent/DK476583A/da not_active Application Discontinuation
- 1983-10-14 BG BG6264983A patent/BG49708A3/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR2534589B1 (fr) | 1988-12-16 |
| BE897980A (fr) | 1984-01-30 |
| ES526481A0 (es) | 1984-08-01 |
| SE8305665D0 (sv) | 1983-10-14 |
| DE3337506C2 (de) | 1991-07-04 |
| FI80830B (fi) | 1990-04-30 |
| AT385655B (de) | 1988-05-10 |
| BG49708A3 (en) | 1992-01-15 |
| DE3337506A1 (de) | 1984-04-19 |
| HU187167B (en) | 1985-11-28 |
| FR2534589A1 (fr) | 1984-04-20 |
| SE8305665L (sv) | 1984-04-16 |
| ATA363983A (de) | 1987-10-15 |
| FI833707A (fi) | 1984-04-16 |
| FI80830C (fi) | 1990-08-10 |
| GB2129821A (en) | 1984-05-23 |
| GB2129821B (en) | 1986-02-19 |
| ES8406196A1 (es) | 1984-08-01 |
| GB8327633D0 (en) | 1983-11-16 |
| FI833707A0 (fi) | 1983-10-12 |
| DK476583D0 (da) | 1983-10-14 |
| DK476583A (da) | 1984-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Harris et al. | Ferric ion sequestering agents. 6. The spectrophotometric and potentiometric evaluation of sulfonated tricatecholate ligands | |
| JP6655617B2 (ja) | Ｇｄ−ＤＯＴＡ金属錯体のメグルミン塩を含む製剤 | |
| US20070207993A1 (en) | Molybdenum carbonyl complexes for treating rheumatoid arthritis and other inflammatory diseases | |
| NL8303657A (nl) | Voor injectie geschikte, stabiele, waterige, zoutzuur bevattende oplossing van cisplatine, alsmede werkwijze ter bereiding daarvan. | |
| SE462140B (sv) | Foerfarande foer framstaellning av en loesning foer terapeutiskt bruk innehaallande nya flerkaerniga jaern(iii)blandkomplex med lakt obionsyraligand, som aktiv bestaandsdel | |
| Terato et al. | Studies on iron absorption: I. The role of low molecular polymer in iron absorption | |
| JP2002527482A (ja) | 透析用緩衝化組成物 | |
| JPH111487A (ja) | Ｌ−アスコルビン酸−２−リン酸亜鉛塩及びその製造方法 | |
| CN109010362A (zh) | 一种小儿复方电解质葡萄糖注射液及其制备方法 | |
| CN105520955B (zh) | 一种羧基麦芽糖铁药用组合物及其制备方法 | |
| CN109091500A (zh) | 一种小儿复方电解质葡萄糖注射液及其制备方法 | |
| RU2611839C1 (ru) | Состав для производства йодосодержащих биологически активных добавок | |
| CN111375071B (zh) | 一种制备造影剂方法 | |
| Djurdjević et al. | Solution equilibria between aluminum (III) ion and some fluoroquinolone family members. Spectroscopic and potentiometric study | |
| Inoue et al. | Magnetically different crystal modifications of copper (II) salicylate | |
| Di Marco et al. | Complexation of aluminium (III) with 3-hydroxy-2 (1 H)-pyridinone. Solution state study and crystal structure of tris (3-hydroxy-2 (1 H)-pyridinonato) aluminium (III) | |
| DE2259151A1 (de) | Verfahren zur herstellung eines antibiotikum-derivates | |
| CN104402894A (zh) | 3-(1-烷氧乙基)二氢卟吩e6类似物的金属络合物及其制备方法和应用 | |
| RU2072993C1 (ru) | Способ получения соли 1, 4, 10, 13-тетраокса-7,16-диазациклооктадекан-n,n'-дималоновой кислоты | |
| CN114195807B (zh) | 一种球状稀土团簇及其制备方法和在制备核磁共振成像造影剂中的应用 | |
| JPS59116221A (ja) | 白金またはパラジウム錯体 | |
| Camper et al. | Sorption of substituted phenylamides onto bovine serum albumin | |
| DE255030C (de) | ||
| Mellor et al. | Effects of antibiotic treatment on the composition of sheep foetal fluids | |
| SU713152A1 (ru) | Свинцова соль @ -амино- @ -фенилпропионовой кислоты, про вл юща канцеролитическое действие |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |
Ref document number: 8305665-5 Effective date: 19920510 Format of ref document f/p: F |